Last reviewed 2026-06-10 · How we verify

Non-Hyperkeratotic Actinic Keratoses — Treatment Landscape & Competitive Intelligence

Non-Hyperkeratotic Actinic Keratoses (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Non-Hyperkeratotic Actinic Keratoses, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Abramson Cancer Center at Penn Medicine · 1 drug in Non-Hyperkeratotic Actinic Keratoses
2. Sherrif Ibrahim · 1 drug in Non-Hyperkeratotic Actinic Keratoses
3. Sun Pharma · 1 drug in Non-Hyperkeratotic Actinic Keratoses

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Non-Hyperkeratotic Actinic Keratoses:

• Non-Hyperkeratotic Actinic Keratoses treatment updates — RSS
• Non-Hyperkeratotic Actinic Keratoses treatment updates — Atom
• Non-Hyperkeratotic Actinic Keratoses treatment updates — JSON

Cite this brief

Drug Landscape (2026). Non-Hyperkeratotic Actinic Keratoses — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/non-hyperkeratotic-actinic-keratoses. Accessed 2026-06-10.

Related

• Non-Hyperkeratotic Actinic Keratoses full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing